SCHEMBL1945253

SCHEMBL1945253

FC(F)(F)Oc1cccc(-c2cn3nc(NCC4CC4)sc3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 19/20 0.47
F2RL3 Q96RI0 1/20 0.46
PIM2 Q9P1W9 6/20 0.45
KCNH2 Q12809 4/20 0.45
FLT3 P36888 2/20 0.45
PIM3 Q86V86 2/20 0.45
GAK O14976 1/20 0.45
STK10 O94804 1/20 0.45
YES1 P07947 1/20 0.45
RET P07949 1/20 0.45
PDGFRB P09619 1/20 0.45
CSNK2A2 P19784 1/20 0.45
ACVR1 Q04771 1/20 0.45
PKN1 Q16512 1/20 0.45
HASPIN Q8TF76 1/20 0.45
SIK2 Q9H0K1 1/20 0.45
SLK Q9H2G2 1/20 0.45
BMP2K Q9NSY1 1/20 0.45
PRKAG2 Q9UGJ0 1/20 0.45
RPS6KA6 Q9UK32 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944168 0.94 PIM1 (0.55) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL625504 0.94 PIM1 (0.56) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL624879 0.91 PIM1 (0.50) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL624837 0.89 PIM1 (0.47) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL624533 0.87 PIM1 (0.53) PIM1PIM2KCNH2FLT3PIM3
SCHEMBL624042 0.87 PIM1 (0.48) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL624816 0.86 PIM1 (0.51) PIM1F2RL3PIM2KCNH2FLT3
SCHEMBL17004610 0.85 F2RL3 (0.57) PIM1F2RL3PIM2
SCHEMBL1947246 0.84 F2RL3 (0.55) F2RL3
SCHEMBL1945626 0.83 F2RL3 (0.47) PIM1F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2193133-B1 IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) 2015-08-19 EP disclosed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R PIM1 72/4885F2RL3 1121/4885PIM2 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.